Anixa Biosciences (ANIX) Return on Capital Employed (2011 - 2026)
Anixa Biosciences' (ANIX) quarterly Return on Capital Employed came in at 78.46% in Q2 2026, up 341.0% YoY from 17.79% in Q2 2025, and little changed on a QoQ basis from 78.54% in Q4 2025.
Anixa Biosciences (ANIX) Return on Capital Employed (2011 - 2026) Analysis & Trends
Anixa Biosciences (ANIX) has 16 years of Return on Capital Employed data on file, last reported at 78.46% in Q2 2026.
- Quarterly Return on Capital Employed rose 341.0% year-over-year to 78.46% in Q2 2026, while the trailing twelve-month figure through Apr 2026 was 78.46% (up 341.0% YoY) and the FY2025 annual result came in at 69.37%, down 368.0% from the prior year.
- Return on Capital Employed steadied at 78.46% in Q2 2026, from 78.54% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 43.53% in Q1 2022 to a low of 81.87% in Q2 2025.
- A 5-year average of 58.66% and a median of 50.72% in 2024 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2022 — Return on Capital Employed jumped 4770 bps — and 2025, when it tumbled 2592 bps.
- Tracing ANIX's Return on Capital Employed over 5 years: stood at 47.11% in 2022, then advanced by 3 bps to 45.84% in 2023, then plunged by 53 bps to 70.03% in 2024, then fell by 12 bps to 78.54% in 2025, then increased by 0 bps to 78.46% in 2026.
- The last three Return on Capital Employed figures came in at 78.46% (Q2 2026), 78.54% (Q4 2025), and 78.62% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.83 Bn | 130.98 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.79 Bn | 77.79 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.95 Bn | 59.77 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.59 Bn | 53.46 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.93 Bn | 36.83 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.52 Bn | 28.21 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 27.98 Bn | 9.58 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 7.88% |
| 10 | Anixa Biosciences | 125.30 Mn | 125.30 Mn | - | -78.46% |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | -78.46% |
| Oct 31, 2025 | -78.54% |
| Jul 31, 2025 | -78.62% |
| Apr 30, 2025 | -81.87% |
| Jan 31, 2025 | -74.57% |
| Oct 31, 2024 | -70.03% |
| Jul 31, 2024 | -63.43% |
| Apr 30, 2024 | -55.95% |
| Jan 31, 2024 | -50.72% |
| Oct 31, 2023 | -45.84% |
| Jul 31, 2023 | -45.85% |
| Apr 30, 2023 | -43.62% |
| Jan 31, 2023 | -44.62% |
| Oct 31, 2022 | -47.11% |
| Jul 31, 2022 | -45.95% |
| Apr 30, 2022 | -48.54% |
| Jan 31, 2022 | -43.53% |
| Oct 31, 2021 | -37.12% |
| Jul 31, 2021 | -30.90% |
| Apr 30, 2021 | -37.23% |